Synonym
Aurintricarboxylic acid; ATA; NSC-4056; NSC 4056; NSC4056;
IUPAC/Chemical Name
5-[(3-Carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-2-hydroxybenzoic acid
InChi Key
GIXWDMTZECRIJT-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H14O9/c23-16-4-1-10(7-13(16)20(26)27)19(11-2-5-17(24)14(8-11)21(28)29)12-3-6-18(25)15(9-12)22(30)31/h1-9,23-24H,(H,26,27)(H,28,29)(H,30,31)
SMILES Code
O=C(O)C1=CC(/C(C2=CC=C(O)C(C(O)=O)=C2)=C3C=C(C(O)=O)C(C=C/3)=O)=CC=C1O
Purity
>85% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
422.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yoo J, Kim JH, Robertson KD, Medina-Franco JL. Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. Adv Protein Chem Struct Biol. 2012;87:219-47. doi: 10.1016/B978-0-12-398312-1.00008-1. Review. PubMed PMID: 22607757; PubMed Central PMCID: PMC3837394.
2: Zhan P, Li Z, Liu X. Cosalane and its analogues: a unique class of anti-HIV agents. Mini Rev Med Chem. 2010 Sep;10(10):966-76. Review. PubMed PMID: 20540707.
3: De Clercq E. The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev. 2011 Jan;31(1):118-60. doi: 10.1002/med.20179. Review. PubMed PMID: 19844936.
4: Clemetson KJ, Clemetson JM. Platelet GPIb complex as a target for anti-thrombotic drug development. Thromb Haemost. 2008 Mar;99(3):473-9. doi: 10.1160/TH07-12-0718. Review. PubMed PMID: 18327394.
5: De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006 Apr;4(2):291-302. Review. PubMed PMID: 16597209.
6: Matsuno H. [Pharmacological analysis of integrin function: inhibition of vascular stenosis and identification of a novel antiplatelet substance]. Nihon Yakurigaku Zasshi. 2000 Mar;115(3):143-50. Review. Japanese. PubMed PMID: 10876799.
7: Hoylaerts MF. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor. Verh K Acad Geneeskd Belg. 1997;59(3):161-83. Review. PubMed PMID: 9490916.
8: Cidlowski JA, King KL, Evans-Storms RB, Montague JW, Bortner CD, Hughes FM Jr. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog Horm Res. 1996;51:457-90; discussion 490-1. Review. PubMed PMID: 8701091.
9: De Clercq E, Snoeck R. [Current acquisitions in antiviral drugs (anti-HIV)]. J Pharm Belg. 1992 Jul-Aug;47(4):317-22. Review. French. PubMed PMID: 1383488.
10: Phelps KR, Vigorita VJ, Bansal M, Einhorn TA. Histochemical demonstration of iron but not aluminum in a case of dialysis-associated osteomalacia. Am J Med. 1988 Apr;84(4):775-80. Review. PubMed PMID: 3041812.
11: De Clercq E. Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem. 1986 Sep;29(9):1561-9. Review. PubMed PMID: 2427720.
12: Clark RA, Krueger GL. Aluminon: its limited application as a reagent for the detection of aluminum species. J Histochem Cytochem. 1985 Jul;33(7):729-32. Review. PubMed PMID: 3891845.
